RxDoctor Payments Data

Kara Johnson, MD

Pulmonary Disease · Fargo, NDNPI 1578708228

Payments from drug & device makers

What this record shows

This record is dominated by education: $2,681 of the $4,306 with a category attached, or 62.3%. Intuitive Surgical accounts for 86.5% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $3,620, more than ten times the $182 reported in 2019.

$4,306in general payments, 2019–2025

Across 31 payments — averaging $138.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • AstraZeneca$153
  • Insmed, Inc.$97
  • United Therapeutics Corporation$74
  • Sanofi-aventis U.S. LLC$57
  • Regeneron Healthcare Solutions, Inc.$36
  • plus $162 from 7 others
$180in research payments, 2019–2025

Across 1 payment — averaging $179.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$180

What the payments were for

  • Travel & lodging$1,01324%
  • Food & beverage$61214%
  • Education$2,68162%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,306 in reported general payments places this provider in the 60th percentile of 31 pulmonary disease providers in North Dakota.

See all pulmonary disease providers in North Dakota

Medicare billing

Part B allowed, 2024
$71,745
Medicare patients
784
Services billed
1,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter185$167,906
Breo ElliptaFluticasone/Vilanterol102$59,068
Spiriva RespimatTiotropium Bromide64$52,297
Dupixent SyringeDupilumab11$40,680
Incruse ElliptaUmeclidinium Bromide77$36,686
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$33,878
Spiriva HandihalerTiotropium Bromide47$33,157
DuleraMometasone/Formoterol62$22,574
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr42$22,235
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$20,745
Fluticasone-SalmeterolFluticasone Propion/Salmeterol113$19,235
Arnuity ElliptaFluticasone Furoate39$13,694
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$13,196
Ventolin HfaAlbuterol Sulfate88$7,852
Serevent DiskusSalmeterol Xinafoate16$6,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$24$73,042108 claims
AstraZenecaBreztri Aerosphere, Symbicort$153$39,41672 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 pulmonary disease providers in North Dakota.

Other pulmonary disease in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →